Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tori Fuller"'
Autor:
Caroline Diorio, Tiffaney L. Vincent, Tori Fuller, Rawan Shraim, Tina Glisovic-Aplenc, Theresa Ryan, Kimberly Veliz, Haley Newman, Gerald Wertheim, Hamid Bassiri, Annette Vu, Michael Hogarty, Carl H June, Stephan A. Grupp, Sarah K Tasian, Richard Aplenc, Saar Gill, David T. Teachey
Publikováno v:
Blood. 140:10285-10286
Autor:
Caroline Diorio, Ryan Murray, Mark Naniong, Luis Barrera, Adam Camblin, John Chukinas, Lindsey Coholan, Aaron Edwards, Tori Fuller, Claudia Gonzales, Stephan A. Grupp, Alden Ladd, Melissa Le, Angelica Messana, Faith Musenge, Haley Newman, Yeh-Chuin Poh, Henry Poulin, Theresa Ryan, Rawan Shraim, Sarah K. Tasian, Tiffaney Vincent, Lauren Young, Yingying Zhang, Giuseppe Ciaramella, Jason Gehrke, David T. Teachey
Publikováno v:
Blood. 140(6)
Allogeneic chimeric antigen receptor T-cell (CART) therapies require multiple gene edits to be clinically tractable. Most allogeneic CARTs have been created using gene editing techniques that induce DNA double-stranded breaks (DSBs), resulting in uni
Autor:
Aristotelis Tsirigos, Harrison L. Kilberg, Joanna Pierro, David T. Teachey, Xiaotu Ma, Nikki A. Evensen, Ashfiyah Chowdhury, William L. Carroll, Gunjan Sethia, Jinghui Zhang, Mignon L. Loh, Takaya Moriyama, Sonali Narang, Jason Saliba, Shella Saint Fleur-Lominy, Jun J. Yang, Patrick A. Brown, Tori Fuller, Kjeld Schmiegelow, Anita Qualls, Hannah Fay
Publikováno v:
Mol Cancer Res
The NSD2 p.E1099K (EK) mutation is observed in 10% of acute lymphoblastic leukemia (ALL) samples with enrichment at relapse indicating a role in clonal evolution and drug resistance. To discover mechanisms that mediate clonal expansion, we engineered
Autor:
Richard Aplenc, Tori Fuller, Brent L. Wood, Soo Yeon Im, Stuart S. Winter, Robin Carson, David T. Teachey, Tiffaney Vincent, Stephen P. Hunger, Stephan A. Grupp, Tina Glisovic-Aplenc, Kimberly P. Dunsmore, William L. Carroll, Mignon L. Loh, Terzah M. Horton, Michelle L. Hermiston, Elizabeth A. Raetz, Yunfeng Dai, Shannon L. Maude, Karen L. Bride, Meenakshi Devidas, David M. Barrett
Publikováno v:
Blood. 131(9)
As a consequence of acquired or intrinsic disease resistance, the prognosis for patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) is dismal. Novel, less toxic drugs are clearly needed. One of the most promising emerging
Autor:
Karen L. Bride, Mignon L. Loh, David M. Barrett, Theresa Ryan, Brent L. Wood, Shannon L. Maude, Tiffaney Vincent, Michelle L. Hermiston, David T. Teachey, Stephan A. Grupp, Soo-Yeon L. Im, Tori Fuller
Publikováno v:
Cancer Research. 77:2642-2642
Targeted immunotherapy has become critical for the successful treatment of many forms of cancer, particularly therapeutic antibodies with cytotoxic abilities. No safe and effective immunotherapies have been developed for T-cell acute lymphoblastic le